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Wilms’ tumour is one of the most common solid tumours of childhood. 11p13 (WT1 locus) and 11p15.5 (WT2 locus) are known to
have genetic or epigenetic aberrations in these tumours. In Wilms’ tumours, mutation of the Wilms tumour 1 (WT1) gene at the WT1
locus has been reported, and the WT2 locus, comprising the two independent imprinted domains IGF2/H19 and KIP2/LIT1, can
undergo maternal deletion or alterations associated with imprinting. Although these alterations have been identified in many studies,
it is still not clear how frequently combined genetic and epigenetic alterations of these loci are involved in Wilms’ tumours or how
these alterations occur. To answer both questions, we performed genetic and epigenetic analyses of these loci, together with an
additional gene, CTNNB1, in 35 sporadic Wilms’ tumours. Loss of heterozygosity of 11p15.5 and loss of imprinting of IGF2 were the
most frequent genetic (29%) and epigenetic (40%) alterations in Wilms’ tumours, respectively. In total, 83% of the tumours had at
least one alteration at 11p15.5 and/or 11p13. One-third of the tumours had alterations at multiple loci. Our results suggest that
chromosome 11p is not only genetically but also epigenetically critical for the majority of Wilms’ tumours.
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Wilms’ tumour, also known as nephroblastoma, is one of the most
common solid tumours of childhood, accounting for approxi-
mately 6% of all childhood malignancies. Chromosomal region
11p13 was first identified as a Wilms’ tumour locus, WT1, because
the region was found to be deleted in Wilms’ tumours (Kaneko
et al, 1981; Huff, 1998; Dome and Coppes, 2002, OMIM 194070).
The Wilms tumour 1 (WT1) gene, isolated from the WT1 locus, was
the first causative gene for Wilms’ tumour (Call et al, 1990; Gessler
et al, 1990). However, WT1 aberrations, such as deletions and
point mutations, are observed in only approximately 10–20% of
Wilms’ tumours (Huff, 1998; Nakadate et al, 2001). The small
number of WT1 mutations in Wilms’ tumours suggests that WT1
can be inactivated by alterations that would not be detected by
mutational analysis (Huff, 1998). On the other hand, although WT1
mutation is not frequent, WT1 mutation and CTNNB1 (b-catenin)
mutation at 3p21 are significantly correlated with Wilms’ tumours
(Maiti et al, 2000).
Loss of heterozygosity (LOH) of 11p15.5, which is known as the
WT2 locus (OMIM 194071), is observed in Wilms’ tumours. LOH
occurs on the maternal chromosome, suggesting the involvement
of genomic imprinting in Wilms’ tumorigenesis. This imprinted
region is well characterised, and is divided into two imprinted
domains, IGF2/H19 and KIP2/LIT1 (Feinberg, 2000). It has been
reported that IGF2 and H19 within the IGF2/H19 domain are
expressed abnormally in Wilms’ tumours. IGF2 encodes an
embryonal growth factor and is transcribed exclusively from the
paternal allele (Reik and Murrell, 2000), and H19 is a noncoding
RNA with reciprocal transcription from the maternal allele. In
Wilms’ tumours, abnormally high levels of IGF2 mRNA and loss of
imprinting (LOI) of IGF2, allowing both paternal and maternal
alleles to be transcribed, have been observed (Reeve et al, 1985;
Ogawa et al, 1993; Rainier et al, 1993). LOI of IGF2 is always
accompanied by H19 biallelic hypermethylation, leading to
inactivation of H19 (in the normal situation, the region upstream
of H19 is methylated only on the paternal allele) (Moulton et al,
1994; Steenman et al, 1994). Demethylation of DMR-LIT1,a n
imprinting control region (ICR) of the KIP2/LIT1 domain, occurs
in half of all patients with Beckwith–Wiedemann syndrome (BWS)
(OMIM 130650), which predisposes patients to embryonal
tumours, and in a variety of adult tumours. The p57
KIP2 (KIP2)/
CDKN1C gene within the KIP2/LIT1 domain, which is expressed
predominantly from the maternal allele, encodes a cyclin-
dependent kinase inhibitor and is a putative tumour suppressor.
In several adult tumours, KIP2 expression is epigenetically reduced
(Shin et al, 2000; Kikuchi et al, 2002; Li et al, 2002; Soejima et al,
2004). However, KIP2 expression has been found to be reduced in
Wilms’ tumours in some studies, but not in others (Chung et al,
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s1996; Hatada et al, 1996; Thompson et al, 1996; O’Keefe et al, 1997;
Taniguchi et al, 1997; Soejima et al, 1998).
Although several genes involved in Wilms’ tumour have been
identified, as described above, the alteration frequencies of these
genes (loci) and how many loci are altered in the tumour are still
unknown. To investigate this, we comprehensively investigated
genetic and epigenetic alterations of three loci – WT1 (11p13),
WT2 (11p15.5), and CTNNB1 (3p21) — in 35 sporadic Wilms’
tumours (Figure 1). Our data indicate that genetic and/or
epigenetic alterations of genes at these loci, especially WT1 and
WT2, is involved in the majority of Wilms’ tumours, and that
alterations of multiple loci occur in one-third of tumours. These
findings suggest that genetic and epigenetic alterations on the
short arm of chromosome 11 play an important role in Wilms’
tumorigenesis.
MATERIALS AND METHODS
DNA and RNA
In all, 35 tissue samples from sporadic Wilms’ tumours and five
tissue samples from mid-gestational fetal kidneys were obtained
from Saitama Cancer Center Hospital (Saitama, Japan) and the
fetal tissue bank at the University of Washington, (WA, USA),
respectively. Genomic DNA and total RNA were extracted with a
QIAamp DNA mini kit (Qiagen, Hilden, Germany) and Isogen
(Nippon Gene, Tokyo, Japan), respectively.
Mutation and LOH analyses
Genetic analyses of WT1 were carried out as previously described
(Nakadate et al, 1999, 2001). Briefly, WT1 loci were screened for
mutations by single-strand conformation polymorphism (SSCP)
analysis of all exons and splice-donor/acceptor sites. When an
aberrant band was identified by SSCP, the band was excised and
sequenced. Loss of heterozygosity was also analysed using
polymorphic DNA markers as follows to compare tumour tissue
with adjacent normal tissue or peripheral blood: D11S16, D11S325,
PAX6, D11S324, WT1, and CAT for 11p13; and D11S12, D11S922,
D11S932, IGF2, INS, and TH for 11p15.5. Mutations in exon 3 of
the CTNNB1 gene were investigated by PCR-directed sequencing as
previously described (Satoh et al, 2003).
Quantitative real-time reverse transcription
(RT)–polymerase chain reaction (PCR)
Total RNA (500ng) was treated with RNase-free DNase I (Roche,
Basel, Switzerland) and reverse-transcribed with ReverTra Ace
reverse transcriptase (Toyobo, Japan) and random primers
(TaKaRa, Japan). Quantitative real-time RT–PCR was performed
with the LightCyclert system (Roche) according to the manufac-
turer’s protocol. The expression of WT1 was normalised with that
of b-actin, as previously described (Satoh et al, 2003). The average
WT1 expression of four mid-gestational fetal kidneys was employed
as a standard. All experiments were performed in triplicate.
Allele-specific expression of IGF2
Genotyping of IGF2 was performed by PCR-restriction fragment
length polymorphism (RFLP) using a polymorphic HaeIII (ApaIo r
AvaII) site in exon 9, as previously described (Soejima and Yun,
1998). To eliminate genomic DNA contamination, the RNA-
specific product (1120bp) was amplified by using an exon
connection primer pair (50-TCCTGGAGACGTACTGTGCTA-30
and 50-GGTCGTGCCAATTACATTTCA-30). To further eliminate
contaminating DNA, the RNA-specific product was excised from
1% agarose gel after electrophoresis and purified. Then, the
purified product was subjected to nested PCR and RFLP analysis
with HaeIII (Yun et al, 1999).
Methylation analyses
Combined bisulphite restriction analyses (COBRA) using the
hot-stop method were employed to determine the extent of
methylation at the differentially methylated region (DMR) of the
H19 promoter (H19-pro-DMR), DMR-LIT1, and WT1 promoter.
Although an ICR of the IGF2/H19 domain exists between 2 and
5kb upstream of the H19 gene, we analysed H19-pro-DMR
because IGF2 LOI uniformly correlates with hypermethylation of
H19-pro-DMR (Moulton et al, 1994; Steenman et al, 1994).
The primer pairs and restriction endonucleases used were as
DMR-LIT1
 Methylation
H19-DMR
Mutation
Expression
Methylation
Allelic expression Methylation
(H19-pro-DMR)
Mutation
WT1 KIP2 LIT1 IGF2 H19
cen tel
CTNNB1
tel cen
11p13 (WT1 locus) 11p15.5 (WT2 locus)
KIP2/LIT1 imprinted domain IGF2/H19 imprinted domain
3p21
A Chromosome 11
B Chromosome 3
Figure 1 Maps of regions analysed in this study. (A) WT1 locus and WT2 locus on the short arm of chromosome 11. Representative genes are
shown. Broken arrows indicate transcriptional direction. Grey boxes and shaded boxes indicate maternal and paternal expression, respectively. DMR-LIT1 and
H19-DMR are the ICRs for each domain, respectively. DMR-LIT1 is differentially methylated on the maternal allele. The H19-DMR and H19 promoter are
differentially methylated on the paternal allele. The items examined in this study are shown below each gene or DMR. (B) CTNNB1 locus. Maps are not to scale.
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sfollows: 50-GGGAGGGTTTTGTTTTGATTGGT-30,5 0-ACTCTCCT
CCAACACCCCATCTTC-30, and HinfI for H19-pro-DMR; and 50-
CGTATTCGATTTTGTTCGGATTT-30;5 0-ACTACCCTCAACTTCC
CAAAACT-30, and HinfI for the WT1 promoter. For several
samples, methylation of H19-pro-DMR was confirmed by using
hot-stop COBRA for a region immediately downstream of CTCF
binding site 6 (CTCF6) in H19-DMR. The primer pairs and the
restriction endonuclease used were 50-GAGTTYGGGGGTTTTTG
TATAGT-30,5 0-TAAATAATACCCRACCTAAAAATCTAA-30, and
MluI. DMR-LIT1 was analysed as previously described (Soejima
et al, 2004). The hot-stop COBRA products were separated by 7.5%
polyacrylamide gel electrophoresis (PAGE) and quantified with
BAS2000 (Fujifilm, Japan). All experiments were performed three
times independently.
RESULTS
Genetic and epigenetic alteration of the IGF2/H19
imprinted domain at 11p15.5
Of 35 tumours, 10 (29%) showed LOH of 11p15 and 25 showed
retention of heterozygosity (ROH) at this locus (Tables 1 and 2).
11p15.5 LOH involved loss of both the IGF2/H19 and KIP2/LIT1
imprinted domains. Although three tumours (#33, #34, and #35)
were not informative for polymorphisms, these were considered to
have undergone LOH because of hypermethylation of H19-pro-
DMR and hypomethylation of DMR-LIT1, indicating loss of the
maternal chromosomal region. For another three tumours that
were not informative for polymorphisms (#6, #8, and #10),
methylation of H19-pro-DMR and DMR-LIT1 was maintained, so
they were considered to show ROH.
We examined allelic expression of IGF2 to screen for epigenetic
alterations of the IGF2/H19 imprinted domain. Genotyping
revealed that eight tumours (#1–4, #11–14) were heterozygous
for polymorphism in IGF2 exon 9. Reverse transcription–PCR
revealed that three of these (#12–14) expressed IGF2 biallelicaly,
that is, LOI had occurred (Table 1). We also examined the
methylation status of H19-pro-DMR because IGF2 LOI uniformly
correlates with biallelic hypermethylation of H19-pro-DMR (Moulton
et al, 1994; Steenman et al, 1994). Five normal mid-gestational
fetal kidneys were used as controls for the methylation status of
H19-pro-DMR. The average percentage methylation of the fetal
kidneys was 42.578.4% (data not shown), and we defined
methylation of more than the average of the fetal kidneysþ2s.d.
Table 1 Genetic or epigenetic alterations in Wilms’ tumours
11p15.5 (WT2 locus) 11p13 (WT1 locus) 3p21
Sample no. 11p15.5 LOH IGF2 LOI DMR-LIT1 11p13 LOH WT1 mutation WT1 express.
a CTNNB1 mutation Alteration type
b
1   ROI (p) Normal   128.1   None
2   ROI (p) Normal ND   114.3   None
3   ROI (p) Normal   128.6   None
4   ROI (p) Normal ND   385.7   None
5   ROI (m) Normal    57.1   None
6(  )
c ROI (m) Normal ND   385.7   None
7   ROI (m) Normal    0.0   E
8(  )
c ROI (m) Normal ND   0.0   E
9   ROI (m) Normal HD HD 28.6   G
10 ( )
c ROI (m) Normal HD HD 28.6   G
11   ROI (p) Hypo HD HD 0.0 Pro44Ala Ser45Pro G, G, E
12   LOI (p) Normal    14.3   E
13   LOI (p) Normal    85.7   E
14   LOI (p) Normal    28.6   E
15   LOI (m) Normal    57.1   E
16   LOI (m) Normal   114.3   E
17   LOI (m) Normal   442.9   E
18   LOI (m) Normal NI   28.6   E
19   LOI (m) Normal NI   85.7   E
20   LOI (m) Normal NI   1557.1   E
21   LOI (m) Normal   157.1 Thr41Ala G, E
22   LOI (m) Normal    0.8   E, E
23   LOI (m) Hypo ND   142.9   E
24   LOI (m) Hypo NI   171.4   E
25   LOI (m) Hypo ND   0.6   E, E
26 + Hyper Normal +   1.2
d   G, G, E
27 + Hyper Hypo +   14.3   G, G
28 + Hyper Hypo +   28.6   G, G
29 + Hyper Hypo +   85.8   G, G
30 + Hyper Hypo +   228.6   G, G
31 + Hyper Hypo NI   857.1   G
32 + Hyper Normal ND   5.7   G, E
33 (+)
e Hyper Hypo NI   385.7   G
34 (+)
e Hyper Hypo NI   14.3   G
35 (+)
e Hyper Hypo ND   100.0 Ser45Tyr G, G
Genetic and epigenetic alterations are indicated by blue and red bold, respectively. IGF2 LOI was examined by RT–PCR–RFLP with HaeIII polymorphism (p) or methylation
analysis of H19-pro-DMR (m). Hypermethylation of H19-pro DMR in 11p15.5 LOH cases was not indicated by red color because it was due to LOH. WT1 expression in #11 is
not indicated by red color because the reduction of this sample was secondary alteration caused by a genetic alteration, homozygous deletion. LOI¼loss of imprinting;
hyper¼hypermethylation of H19-pro DMR; hypo¼hypomethylation of DMR-LIT1;N D¼not done; NI¼not informative; HD¼homozygous deletion.
aWT1 expression less
than 10% of fetal kidneys is considered epigenetic alteration.
bGenetic alteration and epigenetic alteration are indicated by G and E, respectively. Number of G or E indicates
number of altered loci.
cThese were considered ROH because methylation of H19-pro-DMR and DMR-LIT1 were maintained.
dThis sample showed promoter hypermethylation.
eThese were considered LOH because of H19-pro-DMR hypermethylation and DMR-LIT1 hypomethylation.
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sas hypermethylation. The total number of tumours showing H19-
pro-DMR hypermethylation was 21, comprising 11 with ROH and 10
with LOH (Table 1, Figure 2A). Because LOH occurs with the
maternal chromosome, only the methylated paternal chromosome
remains in LOH tumour cells, resulting in hypermethylation. Thus,
biallelic hypermethylation leading to IGF2 LOI occurred in 11
tumours with ROH. Indeed, all three tumours (#12, #13, #14) that
were heterozygous for the polymorphism and showed biallelic
expression also showed hypermethylation (data not shown).
Furthermore, representative samples with hypermethylation at
H19-pro-DMR also underwent hypermethylation at H19-DMR
CTCF6 (data not shown). A total of 14 out of 35 tumours (40%)
had LOI (Tables 1 and 2); and LOI occurred in 56% of ROH tumours
(14 out of 25).
Epigenetic alteration of the KIP2/LIT1 imprinted domain
at 11p15.5
We investigated methylation of DMR-LIT1 in the KIP2/LIT1
imprinted domain (Tables 1 and 2, Figure 2B) relative to the
average percentage methylation in fetal kidneys, which was
44.377.5% (data not shown). We defined methylation of less
than the average of the fetal kidneys – 2s.d. as hypomethylation.
Although 12 tumours, eight with LOH and four with ROH, showed
hypomethylation, the four with ROH had biallelic hypomethyla-
tion because maternal DMR-LIT1 is normally methylated. In spite
of LOH, two tumours (#26 and #32) did not have a methylation
level that was less than the average for the fetal kidneys – 2s.d., but
still had a low level of methylation (29.7 and 39.8%). These
findings might be due to contamination with nontumour cells.
We also investigated expression and promoter methylation of
KIP2, because this imprinted gene is a putative tumour suppressor
gene, but no somatic mutation has been found in tumours to date.
KIP2 expression varied from zero to approximately 800% of that of
the control fetal kidneys, and the promoter region was not
methylated in any sample (data not shown). In addition, there was
no correlation between KIP2 expression and DMR-LIT1 methyla-
tion.
A total of 25 (71%) tumours showed alteration of IGF2/H19 or
KIP2/LIT1 or both of the domains, of which 10 showed LOH, 11
showed IGF2 LOI only, one showed DMR-LIT1 hypomethylation
only, and three showed both IGF2 LOI and DMR-LIT1 hypo-
methylation (Table 1).
Genetic and epigenetic alteration of WT1 at 11p13
A total of 20 tumours were informative for polymorphisms on
11p13: 12 of these had preserved heterozygosity and five (25%)
Table 2 Frequency of each genetic or epigenetic alteration in Wilms’ tumours
Locus Alteration
Alteration type (genetic (G)
or epigenetic (E)) Sample number Frequency
11p15.5 (WT2 locus) 11p15.5 LOH G 26–35 10/35 (29%)
IGF2 LOI E 12–25 14/35 (40%)
DMR-LIT1 hypomethylation E 11, 23–25 4/35 (11%)
11p13 (WT1 locus) 11p13 LOH G 26–30 5/20 (25%)
WT1 homozygous deletion G 9–11 3/35 (9%)
WT1 reduction E 7, 8, 22, 25, 26
a, 32 6/35 (17%)
3p21 CTNNB1 mutation G 11, 21, 35 3/35 (9%)
aWT1 promoter in #26 was hypermethylated.
A B
C
#5 #25 #8 #27
− + − + − + − +
13.3 48.8 52.6 0
D #11
C>GT>C
#21
A>G
#35 (reverse)
G>T
Control (forward) Control (reverse)
Methylated
Unmethylated
Methylated
Unmethylated
% methylation
Methylated
Unmethylated
% methylation
#5 #15 #24 #17
− + − + − + − +
44.2 84.1 98.8 98.7
#26 #4 #28 Mk
Figure 2 Representative results of this study. (A) Methylation analysis of the H19-pro-DMR by hot-stop COBRA. Tumour #5 showed normal
methylation, whereas #15, #17, and #24 showed hypermethylation.  : not digested by HinfI, þ: digested by HinfI. (B) Methylation analysis of DMR-LIT1 by
hot-stop COBRA. #5 and #8 showed normal methylation, whereas #25, and #27 showed hypo- or demethylation.  : not digested by AccII, þ: digested
by AccII. (C) Methylation analysis of the WT1 promoter region by COBRA. #4 and #28 showed no methylation, whereas #26 showed methylation.
(D) Mutation analysis of CTNNB1. Arrows indicate bases that were mutated. Control sequences are shown below.
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sshowed 11p13 LOH, and these had concurrent 11p15.5 LOH,
indicating a large LOH region (more than 30Mb) in the short arm
of chromosome 11 (Tables 1 and 2). WT1 gene mutation was also
examined as a genetic alteration. Only three tumours had
homozygous deletion of WT1, as previously described (Nakadate
et al, 1999; Watanabe et al, 2006).
As epigenetic alterations, the expression and promoter methyla-
tion of WT1 were examined. We determined the quantity of WT1
expression normalised with b-actin expression. We defined
expression of less than 10% of that of the control fetal kidneys
as a significant reduction, and found seven tumours with such a
reduction (Table 1). Two tumours (#9 and #10) expressed a certain
level of WT1 in spite of a homozygous deletion, which might be
due to contamination with nontumour cells. Excluding tumours
with homozygous deletions, six tumours (17%) had a reduction in
WT1 expression (Tables 1 and 2). Methylation analysis, however,
revealed that only one tumour (#26) had promoter methylation, as
previously described (Table 1 and Figure 2C) (Satoh et al, 2003).
Promoter methylation was not found in any other tumours with
reduction in WT1 expression.
In summary, genetic alterations of WT1 such as LOH or WT1
homozygous deletion were found in a total of eight tumours, and
epigenetic alterations (i.e. reduction of WT1 expression) were
found in six (Table 2).
CTNNB1 mutation
We found four missense mutations of the CTNNB1 gene in three
tumours: Pro44Ala (CCT to GCT) and Ser45Pro (TCT to CCT) in
#11, Thr41Ala (ACC to GCC) in #21, and Ser45Tyr (TCT to TAT) in
#35 (Tables 1 and 2, Figure 2D). The tumours with CTNNB1
mutation had concurrent WT1 homozygous deletion and DMR-
LIT1 hypomethylation, IGF2 LOI, and 11p15.5 LOH, respectively.
DISCUSSION
In this study, we investigated genetic and epigenetic alterations of
three loci that are thought to be involved in Wilms’ tumour: the
WT2 locus (11p15. 5) including the IGF2/H19 and the KIP2/LIT1
imprinted domains, the WT1 locus (11p13) including the WT1
gene, and 3p21 locus including the CTNNB1 gene. Loss of
heterozygosity of 11p15.5 was the most frequent genetic alteration
(29%), and IGF2 LOI was the most frequent epigenetic alteration
(40%) (Table 2). In ROH tumours only, IGF2 LOI frequency
occurred in approximately 56% of cases (14/25). The data were
consistent with the results of previous reports (Ogawa et al, 1993;
Rainier et al, 1993; Steenman et al, 1994; Moulton et al, 1994, Yuan
et al, 2005). It is intriguing that three tumours (#23–25) showed
alterations of both IGF2/H19 and KIP2/LIT1 imprinted domains,
because each domain is independently regulated, and BWS with
both alterations is very rare (DeBaun et al, 2002). Furthermore, #25
had a reduction of WT1 expression. The data suggest that 11p is
epigenetically unstable in Wilms’ tumours. With regard to the
number of altered loci, 18 tumours (51%) showed alteration at only
one locus and 11 (31%) showed alterations at multiple loci
(Table 3). Six (18%) tumours did not show any alteration. Thus,
83% (29 out of 35) of Wilms’ tumours had alterations at one or
more of the three loci. Furthermore, no tumour had mutation of
CTNNB1 alone. These results indicate that the alterations observed
in Wilms’ tumours are concentrated on the short arm of
chromosome 11, that is 11p15.5-p13, and that the region is not
only genetically but also epigenetically critical for Wilms’
tumorigenesis.
As shown in Figure 3, there were 10 and 15 tumours,
respectively, with only genetic or only epigenetic alterations. Four
tumours had both genetic and epigenetic alterations. The average
age of patients at diagnosis for tumours with only genetic and only
Table 3 Number of altered loci in Wilms’ tumour
Genes and loci One locus Two loci Three loci None
WT2 locus (11p15.5) + + + +  
WT1 locus (11p13) + + + +  
CTNNB1 (3p21) + + + +  
14 4 0 7 2 0 2 6
+Indicates genetic or epigenetic alteration at each locus. WT2 locus: 11p15.5 LOH or IGF2 LOI or DMR-LIT1 hypomethylation. WT1 locus: 11p13 LOH or WT1 mutation or WT1
reduction. CTNNB1: mutation.
Genetic alterations (10)
(#9, #10, #27, #28, #29,
#30, #31, #33, #34, #35)
Epigenetic alterations (15)
(#7, #8, #12, #13, #14,
#15, #16, #17, #18, #19,
#20, #22, #23, #24, #25)
Both (4)
(#11, #21,
#26, #32,)
Noalteration (6)
(#1, #2, #3, #4, #5, #6)
Total (35)
Figure 3 Schematic diagram summarising alterations of the three loci in a total of 35 sporadic Wilms’ tumours. Genetic alterations comprise LOH, WT1
mutation, and CTNNB1 mutation. Epigenetic alterations comprise IGF2 LOI, DMR-LIT1 hypomethylation, and WT1 reduction.
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respectively, but there was no significant difference between them.
Because maternal LOH of 11p15.5 is uniformly accompanied by
paternal duplication, it results in two paternal copies of the IGF2
gene and an increase of IGF2 expression. In addition, IGF2 LOI is
observed in non-neoplastic kidney parenchyma and frequently in
early-stage tumours, indicating the importance of IGF2 in Wilms’
tumorigenesis (Moulton et al, 1994; Okamoto et al, 1997; Yuan
et al, 2005). However, in a recent study, IGF2 LOI was not observed
in any of 21 Wilms’ tumours from Japanese patients (Fukuzawa
et al, 2004). In that study, the HpaII site near the CTCF6 in H19-
DMR, which is approximately 2kb upstream from the H19
transcription initiation site, was used to analyse IGF2 LOI using
real-time PCR. In the present study, we employed RT–PCR–RFLP
and hot-stop COBRA for analysis of the methylation of H19-pro-
DMR. Further, the results of H19-pro-DMR were confirmed by
H19-DMR CTCF6 with hot-stop COBRA. Our results clearly show
that IGF2 LOI occurs in Japanese patients with Wilms’ tumour. At
present, we are not able to explain the discrepancy, but having a
small sample size might have influenced the results.
Although KIP2 expression is epigenetically reduced in several
adult tumours (Shin et al, 2000; Kikuchi et al, 2002; Li et al, 2002;
Soejima et al, 2004), expression levels in Wilms’ tumour as
measured in previous studies have varied (Chung et al, 1996;
Hatada et al, 1996; Thompson et al, 1996; O’Keefe et al, 1997;
Taniguchi et al, 1997; Soejima et al, 1998). In the present study,
KIP2 expression also varied, suggesting that at least in Wilms’
tumour, KIP2 may not be involved.
WT1 gene expression was reduced in six (17%) tumours. It is
noteworthy that the frequency of WT1 reduction in expression is
similar to that of WT1 mutation. WT1 expression reduction is
correlated with predominant stromal histology (Pritchard-Jones
et al, 1990; Miwa et al, 1992). Our tumours comprised one stromal,
two triphasic, and three blastemal types. Although the precise
histologic composition of tumours in the present study was
unknown, whether or not there is a correlation between the WT1
expression reduction and histology is not clear because the
number of tumours was small. Only one tumour (#26) had
promoter hypermethylation, as described previously (Satoh et al,
2003). Since this tumour also had concurrent 11p13 LOH, ‘two-hit’
inactivation (LOH and methylation) led to a reduction of WT1
expression. However, methylation was not found in any other
tumours with WT1 expression reduction, thus promoter methyla-
tion might not be fundamentally involved in WT1 transcriptional
repression. WT1 transcriptional regulation is remarkably complex,
and our knowledge of it is still quite limited (Englert, 1998). Thus,
other unknown mechanisms may be involved in the reduction of
WT1 expression.
A highly significant correlation has been found between WT1
mutation and CTNNB1 mutation in Wilms’ tumours (Maiti et al,
2000). b-Catenin, a product of the CTNNB1 gene, is involved in the
regulation of cell adhesion and in signal transduction through the
WNT pathway. Abrogation of the WNT pathway by CTNNB1
mutations, resulting in reduced serine/threonine phosphorylation,
has been recognised as playing an important role in the
development of many tumours. All CTNNB1 mutations we found
occurred at or near phosphorylation sites. Only one tumour had
concurrent homozygous deletion of the WT1 gene. Whether or not
there is a correlation between the gene mutations is not clear
because the number of tumours with mutations was too small.
In conclusion, genetic and epigenetic alterations of chromosome
11p play an important role in the majority of Wilms’ tumours.
There is a possibility that not only the genes investigated in this
study but also unidentified genes existing in the region with
unknown function also play an important role in Wilms’
tumorigenesis. In addition, six tumours did not have any
alterations at the three loci studied, suggesting the involvement
of genes at other loci. Chromosomes 1p, 4q, 7p, 11q, 14q, 16q,
and 17p are also frequently lost in Wilms’ tumours, and the
RASSF1A tumour suppressor is frequently silenced by promoter
hypermethylation (Ehrlich et al, 2002; Harada et al, 2002;
Wagner et al, 2002; Yuan et al, 2005). Identification of a novel
gene or genes at these loci and those silenced by epigenetic
mechanisms will be helpful to further understand Wilms’
tumorigenesis.
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